The elderly patient with acute coronary syndrome: The greater the risk, the lesser the cure;Il paziente anziano con sindrome coronarica acuta: Maggiore il rischio, minore la cura

Giornale Italiano di Cardiologia

Volumn 7, Issue 4 SUPPL1, 2006, Pages

  Savonitto, Stefano ^a   Colombo, Paola ^a   Bossi, Irene ^a   Klugmann, Silvio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acute coronary syndromes; Elderly; Ischemic heart disease; Myocardial infarction

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HUMAN; IATROGENIC DISEASE; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYNDROME; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; IATROGENIC DISEASE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745099636     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Gruppo di Ricerca del Progetto Registro per gli Eventi Coronarici e Cerebrovascolari. Registro nazionale italiano degli eventi coronarici maggiori: tassi di attacco e letalità nelle diverse aree del paese. Ital Heart J Suppl 2005; 6: 667-73.
2. Di Chiara A, Chiarella F, Savonitto S, et al, on behalf of the BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24: 1616-29.
3. Di Chiara A, Fresco C, Savonitto S, et al, on behalf of the BLITZ-2 Investigators. Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J 2006; 27: 393-405.
4. Oltrona L, Ottani F, Galvani M, on behalf of the Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J 2004; 148: 405-15.
5. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II, The aging heart in health: links to heart disease. Circulation 2003; 107: 346-54.
6. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
7. De Servi S, Cavallini C, Dellavalle A, et al, on behalf of the ROSAI-2 Investigators. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. Am Heart J 2004; 147: 830-6.
8. Savonitto S, Ambrosini V, Marzocchi A et al, on behalf of the IDEA Survey Investigators and the Italian Society of Invasive Cardiology (GISE). Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study. Ital Heart J 2005; 6: 106-18.
9. Bossi I, Piccaluga E, Scatturin M, et al, per gli Investigatori dello Studio IDEA. Procedure interventistiche coronariche percutanee in pazienti anziani: indicazioni cliniche e terapie farmacologiche concomitanti. Lo studio Italian Drug Evaluation in Angioplasty (IDEA). G Ital Cardiol 2006; 7: 136-44.
10. Stenestrand U, Wallentin L, on behalf of the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med 2003; 163: 965-71.
11. Olivari Z, Di Pede F, Schievano E, et al. Epidemiologia ospedaliera dell'infarto miocardico acuto con sopraslivellamento del tratto ST e applicabilità dell'angioplastica primaria nel contesto di rete intraospedaliera: studio prospettico osservazionale e multicentrico VENERE (VENEto acute myocardial infarction REgistry). Ital Heart J 2005; 6 (Suppl 6): 57S-64S.
12. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I, Aging arteries: a "set up" for vascular disease. Circulation 2003; 107: 139-46.
13. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and the International Study Group. N Engl J Med 1992; 327: 1-6.
14. De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992; 19: 289-94.
15. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101: 2239-46.
16. White HD. Thrombolytic therapy in the elderly. Lancet 2000; 356: 2028-30.
17. Estess JM, Topol EJ. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart 2002; 87: 308-11.
18. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with STsegment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
19. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004; 110: 588-636.
20. O'Neill WW, de Boer MJ, Gibbons RJ, et al. Lessons from the pooled outcome of the PAMI, Zwolle and Mayo Clinic randomized trials of primary angioplasty versus thrombolytic therapy of acute myocardial infarction. J Invasive Cardiol 1998; 10 (Suppl A): 4A-10A.
21. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol 2000; 86: 30-4.
22. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (< 2h), intermediate (2-4h) and late (> 4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23: 550-7.
23. Goldenberg I, Matetzky S, Halkin A, et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2003; 145: 862-7.
24. Mehta RH, Granger CB, Alexander KP, Bossone E, White HD, Sketch MH Jr. Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol 2005; 45: 471-8.
25. de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje A, Suryapranata H, Zijlstra F, on behalf of the Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002; 39: 1723-8.
26. Antoniucci D, Valenti R, Santoro GM, et al. Systematic primary angioplasty in octogenarian and older patients. Am Heart J 1999; 138 (Pt 1): 670-4.
27. Tespili M, Guagliumi G, Valsecchi O, et al. In-hospital clinical outcome in elderly patients with acute myocardial infarction treated with primary angioplasty. Ital Heart J 2003; 4: 193-8.
28. Di Pede F, Olivari Z, Schievano E, et al. L'impatto delle diverse strategie riperfusive sull'esito intraospedaliero dell'infarto miocardico acuto con sopraslivellamento del tratto ST nel contesto di rete interospedaliera: studio prospettico osservazionale e multicentrico VENERE (VENEto acute myocardial infarction REgistry). Ital Heart J Suppl 2005: 6: 804-11.
29. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281: 707-13.
30. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26: 1643-50.
31. Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186-95.
32. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA 1996; 275: 1104-12.
33. Giugliano RP, Camargo CA Jr, Lloyd-Jones DM, et al. Elderly patients receive less aggressive medical and invasive management of unstable angina: potential impact of practice guidelines. Arch Intern Med 1998; 158: 1113-20.
34. Hasdai D, Holmes DR Jr, Criger DA, Topol EJ, Califf RM, Harrington RA. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. Am Heart J 2000; 139: 858-66.
35. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
36. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl): 576S-599S.
37. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-65.
38. Bertrand ME, Simoons ML, Fox KA, et al, on behalf of the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
39. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002; 40: 1366-74.
40. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. The PURSUIT Investigators. Circulation 1999; 99: 2371-7.
41. Mak KH, Effron MB, Moliterno DJ. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs Aging 2000; 16: 179-87.
42. Memon MA, Blankenship JC, Wood GC, Frey CM, Menapace FJ. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000; 109: 213-7.
43. Akkerhuis KM, Deckers JW, Lincoff AM, et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA 2001; 286: 78-82.
44. Ragosta M. Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 42: 433-6.
45. Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians: glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol 2003; 42: 428-32.
46. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
47. The Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-22.
48. Van de Werf F, Barron HV, Armstrong PW, et al, on behalf of the ASSENT-2 Investigators. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA with rt-PA. Eur Heart J 2001; 22: 2253-61.
49. Giugliano RP, McCabe CH, Antman EM, et al, on behalf of the Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001; 141: 742-50.
50. Curtis JP, Alexander JH, Huang Y, et al, on behalf of the ASSENT-2 and ASSENT-3 Investigators. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-2 and-3). Am J Cardiol 2004; 94: 279-83.
51. Giugliano RP, Antman EM, McCabe CH, et al. Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase. (abstr) J Am Coll Cardiol 2000; 35 (Suppl A): 407A.
52. Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial hemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003; 24: 1807-14.
53. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
54. White H, on behalf of the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-63.